KIT and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib has indeed changed the fate of patients with GIST and Philadelphia chromosome-positive chronic myeloid leukemia by targeting the oncogenic drivers of these diseases—BCR–ABL1 and KIT and/or PDGFRA—mutations that promote the function of tyrosine kinase activities (11).